MetaCap

Galectin Therapeutics (GALT) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics (RLMD) has outperformed Galectin Therapeutics (GALT) over the past year, losing 38.6% versus a loss of 49.7%. Over five years, GALT leads with a +4.7% price change compared with -86.1% for RLMD. Relmada Therapeutics is the larger company by market cap ($279.5 million vs $271.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GALT-49.72%RLMD-38.64%
+91%+11%-68%
Nov 21, 20251 yearNov 20, 2026
GALT0.00%RLMD-87.15%
+144%+17%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GALT versus RLMD key metrics
MetricGALTRLMD
Share price$2.69$2.62
Market cap$271.35M$279.54M
1-day change-4.27%-15.76%
YTD return-35.34%-45.76%
1-year return-49.72%-38.64%
5-year return+4.67%-86.09%
EPS (TTM)$-0.32$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-30.84M$-57.39M
52-week high$7.13$8.00
52-week low$2.03$2.60
Distance from 52-week high-62.27%-67.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+308.92%+310.31%
Average volume252.31K1.45M
Shares outstanding100.88M106.69M
Employees917
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLMD has outperformed GALT by 11.1 percentage points over the past year.

About Galectin Therapeutics

GALT stock →

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

GALT vs RLMD FAQ

Which is bigger, Galectin Therapeutics or Relmada Therapeutics?

Relmada Therapeutics (RLMD) is larger, with a market capitalization of $279.54M compared with $271.35M for Galectin Therapeutics (GALT).

Which stock has performed better over the past year, GALT or RLMD?

RLMD returned -38.64% over the past 12 months, compared with -49.72% for GALT (price return, excluding dividends). Past performance does not predict future results.

Are Galectin Therapeutics and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons